CASP3 and amyotrophic lateral sclerosis: Additionally, cells treated with the p38 MAPK-specific siRNA and ALS exhibited a reduction in LC3-II levels and an increase in cleaved caspase-3 and PARP levels compared to cells treated with ALS alone (Figure 5E and 5F).